We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Allergy Therapeutics Plc | LSE:AGY | London | Ordinary Share | GB00B02LCQ05 | ORD 0.1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| -0.10 | -2.02% | 4.85 | 43,475 | 16:35:21 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 4.00 | 5.00 | 4.505 | 4.50 | 4.50 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 59.59M | -43.07M | -0.0090 | -5.00 | 235.94M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:35:21 | UT | 1,000 | 4.85 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 01/10/2024 | 07:00 | UK RNS | Allergy Therapeutics PLC Update on funding and preliminary results |
| 17/9/2024 | 07:00 | UK RNS | Allergy Therapeutics PLC Progression of patient cohorts in PROTECT Trial |
| 27/8/2024 | 09:57 | ALNC |  Allergy Therapeutics secures cash to see it through September |
| 27/8/2024 | 07:00 | UK RNS | Allergy Therapeutics PLC Update on funding |
| 22/7/2024 | 16:26 | ALNC | TRADING UPDATES: Croma Security trading well; Fonix to up final payout |
| 22/7/2024 | 07:01 | UK RNS | Allergy Therapeutics PLC Trading update for the year ended 30 June 2024 |
| 22/7/2024 | 07:00 | UK RNS | Allergy Therapeutics PLC Appointment of Nominated Adviser and Sole Broker |
| 04/7/2024 | 14:22 | UK RNS | Allergy Therapeutics PLC Launch of new Company Long Term Incentive Plan |
| 27/6/2024 | 07:00 | UK RNS | Allergy Therapeutics PLC Appointment of Non-Executive Director |
| 10/6/2024 | 09:36 | ALNC | Allergy Therapeutics welcomes peanut allergy vaccine trial results |
Allergy Therapeutics (AGY) Share Charts1 Year Allergy Therapeutics Chart |
|
1 Month Allergy Therapeutics Chart |
Intraday Allergy Therapeutics Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 03/10/2024 | 13:12 | Allergy Therapeutics - AGY - | 5,050 |
| 07/5/2022 | 15:09 | PEANUT PEANUT PEANUT ALLERGY COMPLETE PREVENTION | 1 |
| 06/5/2022 | 11:08 | Allergy Therapeutics | - |
| 26/5/2021 | 11:10 | Argosy Minerals: Aussie Diamond hunter in SoAfrica | 9 |
| 14/7/2016 | 21:04 | Mike Mitchell Panmure Gordon who covers Allergy Therapeutics PLC (LON:AGY) | 1 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 06/10/2024 09:20 by Allergy Therapeutics Daily Update Allergy Therapeutics Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker AGY. The last closing price for Allergy Therapeutics was 4.95p.Allergy Therapeutics currently has 4,766,439,938 shares in issue. The market capitalisation of Allergy Therapeutics is £214,489,797. Allergy Therapeutics has a price to earnings ratio (PE ratio) of -5.00. This morning AGY shares opened at 4.50p |
Posted at 19/9/2024 22:45 by totally banjo Hi Jimmy, do you mean the new funding agreement initially announced on 27th December 2023?I'm no expert but with the various trials ongoing and future approvals to be obtained depending on the trial outcomes doesn't come cheep! There has also been the costs regarding building up the manufacturing facilities to meet the demand for their current products! The longer term funding is in place up to January 2026 with Warrants issued to the lenders at a price of 4p which are exercisable until January 2027. Therefore I assume the share price will stay around the 4p mark until we start getting real positive news from the company, just my take on the situation. |
Posted at 18/9/2024 00:15 by totally banjo Yesterdays Cavendish coverage is basically just a repeat of the AGY update but saying that it's very positive that they appear to be working very well together in promoting the company! The initial coverage note is worth reading as it explains their view on where the company 'could' go if everything works out.As said before in the shorter term it's what happens regarding their current product line in Europe and elsewhere after the various manufacturing improvements, which should see an increase in revenue which will have a positive effect on the share price The products they offer are not just for the summer months as the allergies they protect from cover various causes and seasons, I assume there is a build up factor too for people with certain allergies but will have to look into that statement! |
Posted at 05/9/2024 01:35 by totally banjo Got beat 6-3 at pool tonight :-( but I won singles and doubles games :-)Anyway, in my opinion over the shorter term is seeing increased revenue in Europe due to their expanded manufacturing facilities to facility the demand for their existing products is key! There is so much potential (that word again) for this company to make massive gains for existing and new shareholders regarding the results of their various trials but they will take time (years) before they are revenue generating! If AGY issues the results of the PROTECT trial in Q4 2024 and if it's positive the share price will rocket! As said before, very boring stock to hold but could pay huge and I mean huge dividends from this current share price in a year or three or before if they get bought out! Do your own research as always! |
Posted at 04/9/2024 11:24 by totally banjo The PROTECT trial estimated completion date is a few months into 2025 but this, I believe, is the follow up on subjects after the trial is finished.Therefore it is likely that we will get the results of the trial in Q4 2024 which will, if positive, give AGY exposure on the global stage which should be reflected in the share price I'm very positive for AGY future but it does need highlighting that the various on going trials will take time to become revenue generating. It is also quite possible AGY could be bought out before this time! |
Posted at 03/9/2024 20:14 by totally banjo Hi coinbase, the PROTECT trial is set for completion not until at least March 2025 and then apply for USA FDA approval which will be another year or so.G306 and G309 have to go through German regulators which will possibly start end of this year and take a year or more to complete. I would imagine we will get updates on the above as various goals are met. Over the next year we should see an increase in revenue from Europe due to manufacturing improvements enabling AGY to meet the strong demand for existing products which will/should have a positive effect on the share price The potential for AGY is massive but it's going to take a while,imo |
Posted at 21/8/2024 00:16 by totally banjo The main short term targets, from what I can gather, is that existing European markets should turn AGY into profit by this time next year with news leading up to this via announcements prior. The reason for this is due to the demand for existing products being very high and now with improvements in their manufacturing and distribution network will see this bear fruit, that's the forecast anyway!European and USA approvals for the various new products are another year off or more! If they get the above we are talking 50p++++ per share with a company buy out and in the meantime at least double figures if they return to profitability within Europe next year, that's just my opinion of course! As investments go it's pretty boring but has the potential (that word again) to at least double the share price from here in a year or go exponential in probably the same time frame if results continue to be positive! Edit- the above is just my opinion so please do your own research as anything could happen! |
Posted at 22/7/2024 23:12 by farmergeorge So why the drop in the share price today?Edit; Drop in the AGY sp? |
Posted at 04/7/2024 21:45 by farmergeorge jimmyloser, no details of share price/performance targets are provided for the options to kick in. What we have is: "Vesting is conditional on the satisfaction of performance criteria over a three year period. The vesting of any share options is subject to a share price threshold." Not sure what impact this will have. |
Posted at 29/12/2023 11:31 by vergeltung I have not read the details (not sure they will be public) but assuming all the important points to be covered in the press release, I am encouraged by this development.The new financing is best seen as part debt, part equity. AGY is not a good credit risk. Borrowing money at 12% is not expensive (you would not get a loan from an unconnected commercial lender on this interest alone). So the lending requires an equity 'kicker'. The warrants are worth little until the share price approaches 4p. Imagine selling call options on AGY equity with a strike price of 4p (i.e. about 60% out-of-the-money) - what would their price be? However, once the shares go over 4p the warrants boost the return on the lending. If the share price rises to 6p (more than 2x the current price), for example, the return to the lenders is 62% after 12 months. Greedy! But that is a big 'if'. Furthermore, if the warrants are issued they entitle the lenders to buy new shares at 4p - i.e. if all 1bn warrants are exercised the company receives a further £40m in cash. This funding like an optimistic move - much of the lenders' return depends upon the share price going up 60% from now (2.5p) and I am pleased that the insiders here appear to have confidence that this will happen. I do think this fundraise is good for the company and this seems to be the view of the market. |
Posted at 31/7/2023 20:58 by timbo003 AGM ReportToday's AGM was held at the offices of the company’s solicitors, Cooley (UK) which is located at 22 Bishopgate EC2N 4BQ, it took quite a while to gain access due to various security measures, so if you ever visit anyone in that that building make sure you let them know ahead of your arrival. When I arrived I commented to Peter Jensen (PJ) that I had received no information from AJ Bell (where I hold most of my AGY shares) about the meeting and I was only aware of the meeting through holding a small number of shares as certificates which meant I got a notification through snail mail. PJ then introduced me to the company secretary (Karley Cheeseman) who said she would look into the matter, but judging by the low attendance at the meeting (I was the only retail shareholder present) I suspect I was not the only retail shareholder who had not been informed about the meeting. There were three directors present all non-execs: Peter Jensen, Mary Tavener and Anthony Parker (Southern Fox). Apparently Manuel Llobet (CEO) and Simon Shen (ZQ Capital) joined by video link, but I couldn’t see them and they didn’t appear to participate in the proceedings There were only two resolutions put to shareholders on this occasion, the first was to approve the accounts and the second was to approve the remuneration report. Having just perused the section on director’s remuneration I had a question regarding the performance related portion of the director’s remuneration. For the year in question the CEO was paid approximately £664k, which comprised £388k basic and £276k performance related, so I questioned whether there should have been a performance related payment for any of the executive directors given the appalling share price performance last year. PJ responded by saying that financial year 2022 ended in June 2022 and the factory shut down occurred after the end of the financial year 2022, however for the subsequent year the performance related payment for the CEO would be zero. That seemed like a satisfactory response to me, so I voted to approve resolution 1 and 2. PJ then closed the formal meeting and allocated me about 15 minutes to ask questions about the business. Given the time constraint I had questions on just two topics, 1) the background to the shutdown last year and the apparent lack of forward planning and contingency plans 2) the forthcoming open offer to shareholders. Shutdown: I questioned why they hadn’t stockpiled product before the shutdown or put in place other contingency plans. PJ responded by saying that everything they could say on the matter was laid out in the RNS statements dated 6th April 2022, they were not able to expand on that. It was not through choice they shut down when they did, but it was necessary to do so due to regulatory (MHRA) concerns. Fund raise: I commented that now the share price had risen considerably above the proposed 1p open offer price, and then asked whether they would consider modifying the offer to raise the same amount of money but by issuing (for example) half the number of shares at 2p/share. This would be of particular benefit to shareholders who were not able to participate in the forthcoming raise for whatever reason. PJ turned to the Lawyer (Simon from Cooley UK) to answer that one. Apparently it is not possible as legal documents have now been signed by the company and proposed funders regarding the proposals for a raise at 1p/share. PJ then took the opportunity to state that he intended to take up the offer in full with his 300K shares, I responded by saying that I intended to do likewise but with a smaller shareholding and allocation. I then asked for confirmation that there would be no funds raised from new outside investors (i.e. no accompanying placing which may attract short term flippers), PJ confirmed there would be no accompanying placing. I also asked whether ordinary shareholders would be able to apply for additional excess shares in addition to their basic allocation, the answer was no, all shares not taken up in the open offer would be purchased by ZQ Capital who are underwriting the offer. After the meeting had come to an end, Simon (the lawyer) filled in a couple more gaps on the funding: The open offer cannot/will not take place until they have foreign direct investment (FDI) clearance from four Jurisdictions (interestingly the UK is not one of the four). In theory this should be easy (especially considering the nature of AGY’s business), but in practice it is more prolonged and complicated than anticipated. The company will issue RNS statements on this should there be any significant developments on this which could affect timings. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
